Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2001-08-15
2004-09-28
Nashed, Nashaat T. (Department: 1652)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S015000, C435S016000, C435S017000, C435S025000, C435S026000
Reexamination Certificate
active
06797460
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to drug discovery methods, more specifically to NMR methods for identifying atoms of interest in enzyme ligands for generating and screening combinatorial libraries of bi-ligand drug candidates.
2. Background Information
Widespread and sometimes indiscriminate use of antibiotics has allowed certain strains of disease-causing bacteria to become resistant to commonly available antibiotics. As a result, the need for more effective antimicrobial drugs is becoming more pressing. One approach to developing such drugs is to find compounds that bind to essential enzymes in bacteria. When such enzymes have two adjacent binding sites, it is especially useful to find “bi-ligand” drugs that can bind at both sites simultaneously. Such drugs are likely to bind extremely tightly, inactivating the enzyme and ultimately killing the bacteria.
The rapid discovery and development of bi-ligand drugs has been difficult. Bi-ligand drug candidates have been identified using rational drug design, but previous methods are time-consuming and require a precise knowledge of structural features. When searching for a drug that binds to an enzyme at two binding sites, it would be particularly useful to understand how a ligand binds to the enzyme. Specifically, which atoms in the ligand interact with which portions of the enzyme's binding sites?
Recent advances in nuclear magnetic spectroscopy (NMR) have allowed the determination of the three-dimensional interactions between a ligand and an enzyme in a few instances. However, these efforts have been limited by the size of the enzyme and can take years to map and analyze the complete structure of the complexes of enzyme and ligand.
Thus, there is a need to more rapidly identify which atoms in the ligand interact with which portions of the enzyme binding sites so that focused combinatorial libraries can be generated and screened for more effective drugs. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention provides a method for rapidly identifying drug candidates that can bind to an enzyme having at least two binding sites. The first site on the enzyme is the “common ligand site” where a known ligand can bind to the enzyme, as well as to other related enzymes. The second site is a “specificity ligand site” adjacent to the common ligand site. Thus, the method identifies bi-ligand drug candidates that can bind at both the common ligand site and the specificity ligand site. As a result, the candidates can bind with high affinity to the enzyme. As a further result, the candidates can be used to bind to related enzymes sharing a similar common ligand site.
The bi-ligand drug candidates are screened from a combinatorial library. Like other combinatorial libraries, a number of diverse compounds can be generated off of a core structure. In the case of a bi-ligand library, this core structure can be a mimic of the common ligand. The mimic can then be derivatized with varying groups at a selected point to generate the diversity of drug candidates in the library. The library is “focused” by optimizing the specific points on the mimic where variation occurs.
The optimal points of variation on the ligand are identified by determining which atoms are proximal to the specificity ligand site when the mimic is bound to the common ligand site. These atoms are identified by first determining which amino acids of the enzyme are proximal to the specificity ligand site, and then identifying which atoms on the bound common ligand mimic are proximal to these amino acids. NMR methods using the nuclear Overhauser effect (NOE) are particularly useful for identifying proximal atoms. Accordingly, this technique has been named Nuclear Magnetic Resonance-Structure Oriented Library Valency Engineering or NMR-SOLVE
SM
. As a result of NMR-SOLVE
SM
, the identified proximal atoms can then be used as a point for variation to generate a focused combinatorial library of high affinity drug candidates that can bind to both the common ligand site and the specificity ligand site of an enzyme of interest, as well as related enzymes sharing a similar common ligand site.
REFERENCES:
patent: 5658739 (1997-08-01), Woods, Jr.
patent: 5693515 (1997-12-01), Clark et al.
patent: 5698401 (1997-12-01), Fesik et al.
patent: 5804390 (1998-09-01), Fesik et al.
patent: 97/18469 (1997-05-01), None
patent: 97/18471 (1997-05-01), None
patent: 98/48264 (1998-10-01), None
Appelt et al., “Design of enzyme inhibitors using iterative protein crystallographic analysis,”J. Med. Chem.,34:1925-1934 (1991).
Borman, “Advance in NMR of Macromolecules,”Chem.&Eng. News,76:55:56 (1998).
Chen et al., “Biased combinatorial libraries: novel ligands for the SH3 domain of phosphatidylinositol 3-kinase,”J. Am. Chem. Soc.,115:12591-12592 (1993).
Chen et al., “Mapping of the Binding Interfaces of the Proteins of the Bacterial Phosphotransferase System, HPr and IIAglc,”Biochemistry,32:32-37 (1993).
Combs et al., “Protein structure-based combinatorial chemistry: discovery of non-peptide binding elements to Src SH3 domain,”J. Am. Chem. Soc.,118:287-288 (1996).
Davis et al., “Alterations in chemical shifts and exchange broadening upon peptide boronic acid inhibitor binding to &agr;-lytic protease,”J. Biomolecular NMR,10:21-27 (1997).
Fejzo et al., “The SHAPES strategy: an NMR-based approach for lead generation in drug discovery,”Chem.&Biol.,6(10):755-769 (1999).
Hajduk et al., “High-throughput nuclear magnetic resonance-based screening,”J. Med. Chem.,42(13):2315-2317 (1999).
Hajduk et al., “Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR,”J. Am. Chem. Soc.,119:5818-5827 (1997).
He et al., “Design and synthesis of new leads for PKC bisubstrate inhibitors,”Bioorganic&Medicinal Chemistry Letters,4:2845-2850 (1994).
Hrovat et al., “Backbone dynamics of oxidized and reducedD. vulgarisflavodoxin in solution,”J. Biomolecular NMR,10:53-62 (1997).
Labrou et al., “Molecular modelling for the design of chimaeric biomimetic dye-ligands and their interaction with bovine heart mitochondrial malate dehydrogenase,”Biochem. J.,315:6954-703 (1996).
Labrou et al., “Oxaloacetate Decarboxylase: On the Mode of Interaction with Substrate-Mimetic Affinity Ligands,”Arch. Biochem. Biophys.,321(1) :61-60 (1995).
Labrou et al., “The Interaction ofCandida boidiniiFormate Dehydrogenase with a New Family of Chimeric Biomimetic Dye-Ligands,”Arch. Biochem. Biophys.,316(1):169-178 (1995).
Labrou et al., “Biomimetic-dye affinity chromatography for the purification of mitochondrial L-malate dehydrogenase from bovine heart,”J. Biotechnol.,45:185-194 (1996).
Lee et al., “Rapid corepressor exchange from the trp-repressor/operator complex: an NMR study of [ul-13c/15N]-L-tryptophan,”J. Biomol. NMR,5(4):367-375 (1995).
LeMaster, “Deuteration in protein proton magnetic resonance,”Methods Enzymol.,177:23-43 (1989).
Moore, “NMR techniques for characterization of ligand binding: Utility for lead generation and optimization in drug discovery,”Biopolymers,51(3):221-243 (1999).
Moore, “NMR screening in drug discovery,”Curr. Opin. Biotechnol.,10(1):54-58 (1999).
Morken et al., “Exploring the leucine-proline binding pocket of the Src SH3 domain using structure-based, split-pool synthesis and affinity-based selection,”J. Am. Chem. Soc.,120:30-36 (1998).
Muchmore et al., “Expression and nitrogen-15 labeling of proteins for proton and nitrogen-15 nuclear magnetic resonance,”Methods Enzymol.,177:44-73 (1989).
Pervushin et al., “Attenuated T2relaxation by mutual cancellation of dipole—dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution,”Proc. Natl. Acad. Sci. USA,94:12366-12371 (1997).
Pervushin et al., “Transverse Relaxation-Optimized Spectroscopy (TROSY) for NMR Studies of Aromatic Spin Systems in13C-Labeled Proteins,”J. Am. Chem. Soc.,120:6394-6400 (1998).
Reilly and Fairbrother, “A novel isotope labeling pr
Pellecchia Maurizio
Sem Daniel S.
Tempczyk-Russell Anna
McDermott & Will & Emery
Nashed Nashaat T.
Triad Therapeutics, Inc.
LandOfFree
NMR-solve method for rapid identification of bi-ligand drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NMR-solve method for rapid identification of bi-ligand drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NMR-solve method for rapid identification of bi-ligand drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3224630